Jiangsu CoWin Biotech Co., Ltd. (SHA:688426)
China · Delayed Price · Currency is CNY 17.84
+0.39 (2.23%)
At close: Aug 4, 2026
Jiangsu CoWin Biotech Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,918 | 2,620 | 3,180 | 3,429 | 3,314 | - | |
Market Cap Growth | -26.59% | -17.61% | -7.26% | 3.44% | - | - |
Enterprise Value | 1,211 | 2,050 | 2,576 | 2,245 | 2,963 | - |
Last Close Price | 17.45 | 23.83 | 28.61 | 30.55 | 29.10 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | 20.81 | - |
Forward PE | - | 21.80 | 21.80 | 21.80 | - | - |
PS Ratio | 9.16 | 13.54 | 25.26 | 20.01 | 6.35 | - |
PB Ratio | 1.43 | 1.93 | 2.14 | 2.04 | 1.85 | - |
P/TBV Ratio | 1.49 | 2.01 | 2.25 | 2.10 | 1.90 | - |
P/FCF Ratio | - | - | - | - | 474.27 | - |
P/OCF Ratio | - | - | - | - | 30.87 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 5.78 | 10.59 | 20.46 | 13.10 | 5.68 | - |
EV/EBITDA Ratio | - | - | - | - | 15.62 | - |
EV/EBIT Ratio | - | - | - | - | 16.80 | - |
EV/FCF Ratio | - | - | - | - | 424.05 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.07 |
Debt / EBITDA Ratio | - | - | - | - | 0.20 | 0.27 |
Debt / FCF Ratio | - | - | - | - | 5.84 | 1.99 |
Net Debt / Equity Ratio | -0.53 | -0.64 | -0.47 | -0.57 | -0.78 | -0.59 |
Net Debt / EBITDA Ratio | 7.92 | 8.56 | 4.35 | 8.21 | -7.34 | -2.31 |
Net Debt / FCF Ratio | 7.18 | 9.31 | 4.36 | 5.56 | -199.38 | -15.97 |
Asset Turnover | 0.14 | 0.12 | 0.07 | 0.09 | 0.40 | 0.62 |
Inventory Turnover | 2.39 | 2.33 | 1.61 | 1.60 | 3.77 | 3.34 |
Quick Ratio | 11.79 | 12.83 | 9.27 | 12.29 | 16.79 | 6.59 |
Current Ratio | 13.76 | 13.95 | 9.92 | 12.78 | 17.46 | 7.25 |
Return on Equity (ROE) | -7.42% | -7.83% | -10.20% | -4.83% | 14.58% | 26.16% |
Return on Assets (ROA) | -4.92% | -5.32% | -6.93% | -4.61% | 8.47% | 14.95% |
Return on Invested Capital (ROIC) | -21.71% | -20.95% | -25.25% | -24.73% | 49.24% | 76.26% |
Return on Capital Employed (ROCE) | -8.60% | -9.30% | -12.40% | -8.00% | 9.50% | 22.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -5.21% | -4.10% | -4.94% | -2.46% | 4.81% | - |
FCF Yield | -5.19% | -3.58% | -5.08% | -4.99% | 0.21% | - |
Dividend Yield | - | - | - | - | 1.49% | - |
Buyback Yield / Dilution | 0.70% | 1.70% | 0.93% | -21.20% | -10.07% | -20.59% |
Total Shareholder Return | 0.70% | 1.70% | 0.93% | -21.20% | -8.58% | -20.59% |